Opinion

Video

Case 2: Low-Volume Recurrent mCSPC

Panelists discuss how the management of low-volume recurrent metastatic castration-sensitive prostate cancer (mCSPC) focuses on personalized treatment strategies, including the use of androgen deprivation therapy and targeted therapies, to achieve optimal outcomes while minimizing treatment-related toxicity.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.